Pomanda estimates the enterprise value of CHRONOS THERAPEUTICS LIMITED at £102.1k based on a Turnover of £95.7k and 1.07x industry multiple (adjusted for size and gross margin).
chronos therapeutics limitedEstimated Valuation
£0
Pomanda estimates the enterprise value of CHRONOS THERAPEUTICS LIMITED at £0 based on an EBITDA of £-17.4m and a 4.98x industry multiple (adjusted for size and gross margin).
chronos therapeutics limitedEstimated Valuation
£627.9k
Pomanda estimates the enterprise value of CHRONOS THERAPEUTICS LIMITED at £627.9k based on Net Assets of £359.6k and 1.75x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Chronos Therapeutics LimitedOverview
Chronos Therapeutics Limited is a live company located in nether alderley, SK10 4TG with a Companies House number of 06838479. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in March 2009, it's largest shareholder is
theracryf plc
with a 100% stake. Chronos Therapeutics Limited is a established,
micro sized company, Pomanda has estimated its turnover at
£95.7k with
healthy
growth in recent years.
Pomanda's financial health check has awarded Chronos Therapeutics Limited a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 5 areas for improvement. Company Health Check FAQs
Health Rating2.5out of 5
2 Strong
3 Regular
5 Weak
Size
annual sales of £95.7k, make it smaller than the average company (£4.4m)
£95.7k - Chronos Therapeutics Limited
£4.4m - Industry AVG
Growth
3 year (CAGR) sales growth of 6%, show it is growing at a similar rate (6.9%)
6% - Chronos Therapeutics Limited
6.9% - Industry AVG
Production
with a gross margin of 49.8%, this company has a comparable cost of product (49.8%)
49.8% - Chronos Therapeutics Limited
49.8% - Industry AVG
Profitability
an operating margin of -18278.9% make it less profitable than the average company (3.3%)
-18278.9% - Chronos Therapeutics Limited
3.3% - Industry AVG
Employees
with 1 employees, this is below the industry average (42)
1 - Chronos Therapeutics Limited
42 - Industry AVG
Pay Structure
on an average salary of £60.7k, the company has an equivalent pay structure (£60.7k)
£60.7k - Chronos Therapeutics Limited
£60.7k - Industry AVG
Efficiency
resulting in sales per employee of £95.7k, this is less efficient (£118.8k)
£95.7k - Chronos Therapeutics Limited
£118.8k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Chronos Therapeutics Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 70 days, this is slower than average (40 days)
70 days - Chronos Therapeutics Limited
40 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Chronos Therapeutics Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 2 weeks, this is less cash available to meet short term requirements (38 weeks)
2 weeks - Chronos Therapeutics Limited
38 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 31.5%, this is a lower level of debt than the average (38.6%)
31.5% - Chronos Therapeutics Limited
38.6% - Industry AVG
CHRONOS THERAPEUTICS LIMITED financials
EXPORT
Chronos Therapeutics Limited's latest turnover from March 2024 is estimated at £95.7 thousand and the company has net assets of £359.6 thousand. According to their latest financial statements, Chronos Therapeutics Limited has 1 employee and maintains cash reserves of £9.4 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Mar 2024
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Turnover
95,711
94,351
80,843
471,239
1,237,450
1,092,330
1,585,570
1,917,505
1,345,901
1,900,464
3,281,920
1,669,733
767,771
526,996
173,602
Other Income Or Grants
Cost Of Sales
48,081
49,880
43,610
260,673
660,146
581,585
816,380
1,005,398
713,054
1,054,818
1,819,523
902,256
436,881
288,221
96,075
Gross Profit
47,630
44,472
37,233
210,566
577,305
510,746
769,190
912,108
632,847
845,646
1,462,396
767,477
330,890
238,775
77,527
Admin Expenses
17,542,509
149,551
143,654
1,235,434
2,261,073
5,804,330
4,804,841
2,917,316
2,308,200
2,617,414
3,082,896
1,587,137
1,025,659
616,788
264,240
Operating Profit
-17,494,879
-105,079
-106,421
-1,024,868
-1,683,768
-5,293,584
-4,035,651
-2,005,208
-1,675,353
-1,771,768
-1,620,500
-819,660
-694,769
-378,013
-186,713
Interest Payable
Interest Receivable
247
3,431
308
346
4,889
15,186
10,830
10,453
30,742
40,686
29,919
12,570
12,400
9,586
2,363
Pre-Tax Profit
-17,494,632
-101,648
-106,113
-1,024,522
-1,678,879
-5,278,398
-4,024,821
-1,994,755
-1,644,611
-1,731,082
-1,590,581
-807,090
-682,369
-368,427
-184,350
Tax
Profit After Tax
-17,494,632
-101,648
-106,113
-1,024,522
-1,678,879
-5,278,398
-4,024,821
-1,994,755
-1,644,611
-1,731,082
-1,590,581
-807,090
-682,369
-368,427
-184,350
Dividends Paid
Retained Profit
-17,494,632
-101,648
-106,113
-1,024,522
-1,678,879
-5,278,398
-4,024,821
-1,994,755
-1,644,611
-1,731,082
-1,590,581
-807,090
-682,369
-368,427
-184,350
Employee Costs
60,709
63,983
61,477
355,617
811,786
1,197,277
1,125,777
1,418,831
1,134,560
958,279
1,502,347
785,919
409,778
272,271
90,222
Number Of Employees
1
1
1
6
14
21
21
28
23
20
33
17
9
6
2
EBITDA*
-17,418,313
-43,826
-31,107
-410,889
-1,077,822
-5,147,380
-3,883,393
-1,898,996
-1,571,574
-1,671,558
-1,535,757
-768,411
-662,790
-364,484
-179,169
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2024
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Tangible Assets
642
1,284
1,925
15,643
48,454
73,231
110,634
122,256
57,310
18,711
Intangible Assets
504,163
580,729
605,256
640,747
1,163,388
1,678,349
1,613,976
1,773,432
531,905
457,034
414,547
371,108
339,317
184,863
105,616
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
504,163
580,729
605,256
641,389
1,164,672
1,680,274
1,629,619
1,821,886
605,136
567,668
536,803
428,418
358,028
184,863
105,616
Stock & work in progress
Trade Debtors
24
82,500
356,144
578,104
294,485
113,591
96,567
31,078
Group Debtors
Misc Debtors
11,698
5,156
5,907
110,214
324,752
288,250
1,311,755
891,994
829,796
Cash
9,411
58,597
137,465
109,024
583,375
720,378
1,002,593
3,329,261
5,033,350
7,263,445
9,010,876
2,956,758
2,071,157
2,889,034
945,203
misc current assets
total current assets
21,109
63,753
143,372
219,238
908,127
1,008,652
2,314,348
4,221,255
5,945,646
7,619,589
9,588,980
3,251,243
2,184,748
2,985,601
976,281
total assets
525,272
644,482
748,628
860,627
2,072,799
2,688,926
3,943,967
6,043,141
6,550,782
8,187,257
10,125,783
3,679,661
2,542,776
3,170,464
1,081,897
Bank overdraft
Bank loan
Trade Creditors
9,279
7,078
942
6,828
114,628
104,575
72,874
14,379
144,806
136,670
344,114
71,389
85,927
31,246
22,599
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
156,349
2,000
10,634
10,634
90,484
148,027
181,192
68,790
total current liabilities
165,628
9,078
11,576
17,462
205,112
252,602
254,066
83,169
144,806
136,670
344,114
71,389
85,927
31,246
22,599
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities
165,628
9,078
11,576
17,462
205,112
252,602
254,066
83,169
144,806
136,670
344,114
71,389
85,927
31,246
22,599
net assets
359,644
635,404
737,052
843,165
1,867,687
2,436,324
3,689,901
5,959,972
6,405,976
8,050,587
9,781,669
3,608,272
2,456,849
3,139,218
1,059,298
total shareholders funds
359,644
635,404
737,052
843,165
1,867,687
2,436,324
3,689,901
5,959,972
6,405,976
8,050,587
9,781,669
3,608,272
2,456,849
3,139,218
1,059,298
Mar 2024
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Operating Activities
Operating Profit
-17,494,879
-105,079
-106,421
-1,024,868
-1,683,768
-5,293,584
-4,035,651
-2,005,208
-1,675,353
-1,771,768
-1,620,500
-819,660
-694,769
-378,013
-186,713
Depreciation
642
642
642
16,285
35,283
82,405
62,144
59,563
49,635
21,183
6,237
Amortisation
76,566
61,253
74,672
613,337
605,304
129,919
116,975
23,807
41,635
40,647
35,108
30,066
25,742
13,529
7,544
Tax
Stock
Debtors
11,698
-751
-104,307
-214,538
36,478
-603,720
419,761
-20,302
556,152
-221,960
283,619
180,894
17,024
65,489
31,078
Creditors
9,279
6,136
-5,886
-107,800
10,053
90,196
58,495
-130,427
8,136
-207,444
272,725
-14,538
54,681
8,647
22,599
Accruals and Deferred Income
156,349
-8,634
-79,850
-57,543
79,237
112,402
68,790
Deferred Taxes & Provisions
Cash flow from operations
-17,264,383
-45,573
67,314
-384,001
-1,161,790
-4,374,227
-4,132,257
-1,940,331
-2,119,590
-1,657,042
-1,546,651
-963,843
-625,133
-421,326
-187,648
Investing Activities
capital expenditure
-580,729
-36,726
-39,181
-90,696
-90,344
-4,592
40,009
-1,322,962
-141,247
-131,075
-193,128
-121,639
-205,144
-92,776
-113,160
Change in Investments
cash flow from investments
-580,729
-36,726
-39,181
-90,696
-90,344
-4,592
40,009
-1,322,962
-141,247
-131,075
-193,128
-121,639
-205,144
-92,776
-113,160
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
17,854,276
1,110,242
1,754,750
1,754,750
1,548,751
7,763,978
1,958,513
2,448,347
1,243,648
interest
247
3,431
308
346
4,889
15,186
10,830
10,453
30,742
40,686
29,919
12,570
12,400
9,586
2,363
cash flow from financing
17,854,523
3,431
308
346
1,115,131
1,769,936
1,765,580
1,559,204
30,742
40,686
7,793,897
1,971,083
12,400
2,457,933
1,246,011
cash and cash equivalents
cash
9,411
-78,868
28,441
-474,351
-137,003
-2,608,883
-2,326,668
-1,704,089
-2,230,095
-1,747,431
6,054,118
885,601
-817,877
1,943,831
945,203
overdraft
change in cash
9,411
-78,868
28,441
-474,351
-137,003
-2,608,883
-2,326,668
-1,704,089
-2,230,095
-1,747,431
6,054,118
885,601
-817,877
1,943,831
945,203
chronos therapeutics limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for chronos therapeutics limited. Get real-time insights into chronos therapeutics limited's credit score, group structure and payment trends.
Perform a competitor analysis for chronos therapeutics limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in SK10 area or any other competitors across 12 key performance metrics.
chronos therapeutics limited Ownership
CHRONOS THERAPEUTICS LIMITED group structure
Chronos Therapeutics Limited has no subsidiary companies.
The sole shareholder of Chronos Therapeutics Limited is Theracryf Plc.
theracryf plc
100%
chronos therapeutics limited directors
Chronos Therapeutics Limited currently has 2 directors.
The longest serving directors include
Ms Toni Haenninen (Apr 2024) and
Dr Huw Jones (Apr 2024).
theracryf plc alderley park, congleton road, nether alderley, SK10 4TG
Bank
-
Legal Advisor
-
chronos therapeutics limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to chronos therapeutics limited.
chronos therapeutics limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for CHRONOS THERAPEUTICS LIMITED. This can take several minutes, an email will notify you when this has completed.
chronos therapeutics limitedCompanies House Filings - See Documents
